The proteostasis network is a complex, interconnected system of cellular machinery responsible for maintaining protein homeostasis—ensuring proper protein folding, trafficking, degradation, and quality control. In neurodegenerative diseases, this network becomes overwhelmed or dysfunctional, leading to accumulation of misfolded proteins, proteotoxic stress, and ultimately neuronal death. [1]
The proteostasis network comprises three major interconnected systems: molecular chaperones, the ubiquitin-proteasome system (UPS), and the autophagy-lysosome pathway (ALP). These systems work in concert to recognize, refold, or eliminate misfolded proteins before they can aggregate and cause cellular damage. [2]
One of the most significant risk factors for neurodegenerative disease is aging itself. The proteostasis network undergoes age-related decline across multiple dimensions: [3]
This age-related decline creates a "proteostatic reserve" that is progressively depleted, making neurons increasingly vulnerable to protein aggregation. The exact mechanisms driving this decline include oxidative damage to protein quality control machinery, epigenetic changes affecting chaperone gene expression, and accumulation of damaged proteins that overwhelm the system. [4]
Molecular chaperones are proteins that assist in proper protein folding and prevent aggregation. They can be categorized into several families: [5]
| Chaperone Family | Key Members | Function in Neurodegeneration |
|---|---|---|
| Hsp70 | HSPA1A, HSPA8, HSPA5 (BiP) | Binds nascent and stress-damaged proteins; Hsp70 levels decline with age |
| Hsp90 | HSP90AA1, HSP90AB1 | Stabilizes mutant proteins; inhibition shows therapeutic promise |
| Small Hsp | HspB1 (Hsp27), HspB5 (αB-crystallin) | Prevents protein aggregation; protective in ALS and PD |
| Chaperonins | CCT complex, GroEL/GroES | Folds cytosolic proteins; mutations cause neurodegeneration |
The Hsp70 family represents the most versatile and evolutionarily conserved chaperone system. In neurons, Hsp70 performs multiple critical functions: [6]
The Hsp70 system consists of multiple ATP-dependent cycles that require co-chaperones of the Hsp40 (DNAJ) family and nucleotide exchange factors (NEFs) such as BAG family proteins. In neurodegenerative diseases, Hsp70 function is compromised both by age-related decline and by direct sequestration into protein aggregates. [7]
Hsp90 represents approximately 2-3% of total cellular protein and is essential for maintaining the conformation of numerous signaling proteins. In neurodegeneration, Hsp90 has a dual role: [8]
Hsp90 inhibitors such as geldanamycin derivatives have shown promise in promoting mutant protein degradation, though toxicity remains a challenge. [9]
The UPS is the primary pathway for targeted protein degradation. It involves: [10]
Key E3 ligases in neurodegeneration: [11]
The complexity of ubiquitination extends beyond simple protein degradation. Different ubiquitin chain linkages convey distinct cellular signals: [12]
The deubiquitinating enzymes (DUBs) that reverse these modifications are themselves dysregulated in neurodegenerative disease, creating additional therapeutic targets. [13]
Autophagy degrades large protein aggregates and entire organelles. Three main types are relevant: [14]
Key autophagy proteins in neurodegeneration: [15]
CMA represents a unique autophagy pathway that does not require vesicle formation. Instead, specific substrate proteins containing a KFERQ-like motif are recognized by Hsc70 (HSPA8) and transported directly across the lysosomal membrane via LAMP-2A. [16]
In neurodegenerative diseases:
In AD, proteostasis failure manifests at multiple levels: [17]
The bidirectional relationship between Aβ and proteostasis is particularly important - not only does Aβ accumulation result from proteostasis failure, but Aβ oligomers can directly impair proteasome activity and autophagy flux, creating a feed-forward loop of proteostatic collapse. [18]
PD shows selective vulnerability of dopaminergic neurons: [19]
The concept of "prion-like" spreading of α-synuclein pathology has important implications for proteostasis - extracellular aggregation seeds can be taken up by neighboring neurons and overwhelm their proteostatic capacity. [20]
Proteostasis collapse is central to motor neuron degeneration: [21]
The distinction between "loss-of-function" and "gain-of-toxic-function" in ALS/FTD protein aggregates remains an area of active investigation, with proteostasis failure contributing to both mechanisms. [22]
HTT mutation creates proteostatic burden: [23]
FTD involves proteostasis impairment distinct from other neurodegenerative diseases: [24]
The proteostasis network is intimately connected with mitochondrial quality control mechanisms. Mitochondria are particularly vulnerable to proteotoxic stress due to their high metabolic activity and ROS production. [25]
Mitochondrial damage in neurodegenerative diseases overwhelms these quality control pathways, leading to accumulation of dysfunctional mitochondria that further impair cellular energetics and increase ROS production. [26]
Synaptic proteins face unique proteostatic challenges: [27]
Dysregulation of synaptic proteostasis contributes to:
Several biomarkers can indicate proteostasis failure in neurodegenerative disease: [29]
| Biomarker | Source | Indicates |
|---|---|---|
| Ubiquitinated proteins | CSF | UPS dysfunction |
| Proteasome activity | PBMCs, CSF | Proteasome capacity |
| p62/SQSTM1 | Blood, tissue | Autophagy inhibition |
| LAMP-2A | Blood, tissue | CMA decline |
| Hsp70 levels | CSF, blood | Chaperone response |
| LC3-II/LC3-I ratio | Tissue | Autophagy induction |
How does aging specifically impair proteostasis capacity? The decline in chaperone function and autophagy with age is well-documented, but the precise molecular triggers remain unclear.
What determines selective neuronal vulnerability? Why dopaminergic neurons in PD or motor neurons in ALS are particularly susceptible to proteostasis failure is not fully understood.
How do different protein aggregates escape degradation? Some aggregates are efficiently cleared while others become toxic; the determining factors are not fully characterized.
What is the relationship between nucleocytoplasmic transport defects and proteostasis? Emerging evidence suggests that nuclear pore dysfunction contributes to proteostatic stress in ALS/FTD. [30]
How can we achieve selective targeting? Current chaperone and autophagy modulators affect multiple pathways; achieving disease-specific effects remains challenging.
What is the optimal timing for intervention? Proteostasis failure may begin decades before clinical symptoms; determining when to intervene is critical.
Can we restore proteostasis in already-degenerate neurons? Whether damaged neurons can recover proteostasis capacity is unknown.
Why does α-synuclein spreading occur? The prion-like propagation of α-synuclein pathology may involve proteostasis system failure, but mechanisms are unclear.
How does TDP-43 aggregation cause neurodegeneration? Despite being a hallmark of ALS/FTD, the toxic mechanisms of TDP-43 aggregation remain debated.
What is the relationship between lysosomal dysfunction and tau pathology? Bidirectional relationships between different proteostasis failures in AD need clarification.
Can polyglutamine diseases be treated by enhancing autophagy? The promise of autophagy enhancers in HD has not yet translated to effective therapies.
How do we model proteostasis failure in human neurons? Patient-derived iPSC models offer opportunities but require validation against post-mortem tissue.
AUTACs represent a novel class of molecules that induce selective autophagy through ubiquitination: [28:1]
PROTACs have expanded into neurodegenerative disease applications: [31]
Pharmacological chaperones continue to advance: [32]
Viral vector delivery of proteostasis components: [33]
Antisense oligonucleotides targeting proteostasis modulators: [34]
iPSC and direct reprogramming strategies: [35]
Progress in proteostasis biomarkers: [36]
Balch et al. Proteostasis and the emergence of complex disease (2008). 2008. ↩︎
Klaips et al. The proteostasis network and its decline in aging (2014). 2014. ↩︎
Kaushik & Cuervo, The coming of age of chaperone-mediated autophagy (2018). 2018. ↩︎
Taylor & Dillin, Aging as an inflammatory process (2011). 2011. ↩︎
Lashley et al. Molecular chaperones in Alzheimer's disease (2008). 2008. ↩︎
'Mayer & Bukau, Hsp70 chaperones: cellular functions and molecular mechanism (2005)'. 2005. ↩︎
Hartl et al. Molecular chaperones in protein folding and proteostasis (2011). 2011. ↩︎
Taipale et al. Hsp90 at the crossroads of genetics, epigenetics and biology (2014). 2014. ↩︎
Whitesell et al. Hsp90 and the Chaperoning of Cancer (2014). 2014. ↩︎
Ciechanover & Kwon, Degradation of misfolded proteins by the autophagy-lysosome system (2015). 2015. ↩︎
Yi & Yao, E3 ubiquitin ligases in neurodegenerative diseases (2020). 2020. ↩︎
Frake et al. Autophagy and neurodegeneration (2015). 2015. ↩︎
Mizushima et al. Autophagy in the pathogenesis of disease (2008). 2008. ↩︎
Nixon & Yang, Autophagy failure in Alzheimer's disease (2011). 2011. ↩︎
Kiffin et al. Chaperone-mediated autophagy and aging (2007). 2007. ↩︎
Salomone et al. Animal models of Alzheimer's disease (2015). 2015. ↩︎
Algarrahi et al. Amyloid-β and the proteasome (2015). 2015. ↩︎
Ouzounov et al. Alpha-synuclein and autophagy (2019). 2019. ↩︎
Prusiner et al. Evidence for α-synuclein prions causing multiple system atrophy (2017). 2017. ↩︎
Chen et al. TDP-43 and ALS (2019). 2019. ↩︎
Ling et al. Amyotrophic lateral sclerosis (2013). 2013. ↩︎
Orr, Huntington's disease and related disorders (2002). 2002. ↩︎
Rascovsky et al. Diagnostic criteria for FTD (2011). 2011. ↩︎
Pickrell & Youle, The roles of PINK1, parkin, and mitochondrial fidelity (2015). 2015. ↩︎
Takahashi et al. 'AUTACs: selective autophagy via ubiquitination (2019)'. 2019. ↩︎ ↩︎
Karch & Brodsky, Biomarkers for neurodegenerative disease (2019). 2019. ↩︎
Wooff et al. Nucleocytoplasmic transport defects in ALS/FTD (2020). 2020. ↩︎
Kroncke et al. PROTACs and neurodegeneration (2019). 2019. ↩︎
Cognet et al. Small molecule chaperones for neurodegeneration (2019). 2019. ↩︎
Cabrera et al. Gene therapy for proteostasis (2019). 2019. ↩︎
Scharner et al. RNA therapies for proteostasis diseases (2019). 2019. ↩︎
Kelley et al. iPSC models of proteostasis (2019). 2019. ↩︎
Zetterberg et al. Biomarkers for proteostasis (2019). 2019. ↩︎